Clinical trials: Allogeneic Disease
Hematologic Malignancies
Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia
The purpose of this study is to determine if MultiStem® can safely be given to patients with acute leukemia, chronic myeloid leukemia, or myelodysplasia after they have received hematopoietic stem cell transplantation.
- Trial name
- NCT00677859
- Testing
- MultiStem®
- Where
- 6 sites in United States, Belgium
- Volunteers
- 36 people
- Sponsor
- Healios K.K.
Sickle Cell Anemia, Severe Aplastic Anemia
Allogeneic Mixed Chimerism Stem Cell Transplant Using Campath for Hemoglobinopathies & Bone Marrow Failure Syndromes
RATIONALE: Although used primarily to treat malignant disorders of the blood, allogeneic stem cell transplantation can also cure a variety of non-cancerous, inherited or acquired disorders of the blood.
- Conditions
- Sickle Cell Anemia, Severe Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Pure Red Cell Aplasia
- Trial name
- NCT00004143
- Testing
- Campath, Chemo and/or TBI Allo SCT
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- David Rizzieri, MD
Graft-versus-Host Disease
Single-centre Study of Everolimus as GvHD Prophylaxis After Post-Transplantation Cyclophosphamide After Allogeneic SCT
A phase II clinical study to assess the efficacy of short-term everolimus as prophylaxis for Graft-versus-Host disease (GvHD) in addition to post-transplantation cyclophosphamide after allogeneic hematopoietic stem cell…
- Trial name
- OCTET-Ever (NCT02812940)
- Testing
- Everolimus
- Where
- Germany
- Volunteers
- 19 people
- Sponsor
- University of Cologne
Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis
Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
This study is a single-arm, intervention, dose-escalation clinical trial to evaluate the safety of allogeneic CD19/BCMA-targeted CAR-γδT cell in the treatment of relapsed/refractory autoimmune diseases
- Conditions
- Refractory/Relapsed Systemic Lupus Erythematosus, Refractory / Relapsed / Progressive Systemic Sclerosis, Refractory / Relapsing / Progressive Inflammatory Myopathy, Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis
- Trial name
- NCT07490275
- Testing
- Allogeneic CD19/BCMA-targeted CAR-γδT cell injection, Cyclophosphamide, Fludarabine
- Volunteers
- 9 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Limb-threatening Ischemia, Diabetes Mellitus
Bone Marrow Mononuclear Cells vs Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb Ischemia
Patients in the severe stages of Chronic limb-threatening ischemia (CLTI) are prone to amputation and death, leading to poor quality of life and a great socioeconomic burden.
- Trial name
- NCT05631444
- Testing
- Cell-based therapy
- Where
- Colombia
- Volunteers
- 24 people
- Sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Acute Myeloid Leukemia (AML)
VABu Conditioning in Elderly AML HSCT
This is an open-label, multi-center, single-arm clinical study evaluating the efficacy and safety of the VABu conditioning regimen in elderly patients (≥60 years) with acute myeloid leukemia (AML) undergoing allogeneic…
- Trial name
- NCT07583888
- Testing
- VaBU
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Acute Respiratory Distress Syndrome
Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome
The main objective of the study is to assess the feasibility, safety, and tolerability of the administration of HCR040, a drug whose active substance is HC016, allogeneic adipose-derived adult mesenchymal stem cells expanded and…
- Trial name
- NCT04289194
- Testing
- HCR040 (Phase 1), HCR040 (Phase 2)
- Where
- 2 sites in Spain
- Volunteers
- 26 people
- Sponsor
- Histocell, S.L.
GVHD, Acute
Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT
A randomized (1:1) phase II open label study of DSC compared to Investigator choice Best Available Therapy (BAT) in allogeneic hematopoietic stem cell transplant recipients with Grades II-IV steroid refractory acute graft vs.
- Trial name
- 2017-00355 (NCT04118556)
- Testing
- Decidua Stroma Cells (DSC), Best available Treatment (BAT)
- Where
- 4 sites in Denmark, Norway and 1 more
- Volunteers
- 12 people
- Sponsor
- Mats Remberger
Chronic Myeloproliferative Disorders, Leukemia
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
RATIONALE: Giving chemotherapy and total-body irradiation before a donor bone marrow transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Multiple Myeloma and Malignant Plasma Cell Neoplasms, Myelodysplastic Syndromes
- Trial name
- NCT00005622
- Testing
- cyclophosphamide, TBI
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Acute Myeloid Leukemia
Study of GDX012 in Patients With MRD Positive AML
The purpose of this first-in-human study is to assess the safety, tolerability, antileukemic activity and maximum tolerated dose (MTD) of GDX012 in AML patients who are MRD positive by multiparametric flow cytometry.
- Trial name
- NCT05001451
- Testing
- GDX012 Suspension for IV Infusion
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- GammaDelta Therapeutics Limited
Leukemia
Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Interleukin-2 may stimulate a person's white blood cells to kill leukemia cells.
- Trial name
- NCT00005802
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Cytomegalovirus Infection
Alternate Donor Study of Pre-Emptive Cellular Therapy
The purpose of this study is to evaluate the potential clinical benefit of pre-emptive cytomegalovirus (CMV)-specific adoptive cellular therapy following T cell depleted allogeneic hematopoietic stem cell transplantation (HSCT)…
- Trial name
- CMV-ACE/ASPECT (NCT01220895)
- Testing
- CMV-specific T-cells, single infusion following single positive CMV PCR result
- Where
- 9 sites in United Kingdom
- Volunteers
- 52 people
- Sponsor
- Cell Medica Ltd
Rectal Fistula
Mesenchymal Stem Cells (MSCs) for Perianal Fistula
OSSM-001 will be evaluated in a double blind, randomized phase I safety study of a single injection of 100 and 300 million bone marrow derived MSCs in 16 patients with refractory perianal fistulas in the setting of Crohn's…
- Trial name
- NCT05407766
- Testing
- OSSM-001
- Sponsor
- Ossium Health, Inc.
Bacterial Pneumonia
Cx611-0204 SEPCELL Study
The purpose of this randomised, multicentre, double-blind, placebo-controlled, phase Ib/IIa study is to assess the safety, tolerability and efficacy of eASCs (Cx611) administered intravenously as adjunctive therapy, therefore in…
- Trial name
- SEPCELL (NCT03158727)
- Testing
- Cx611
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 84 people
- Sponsor
- Tigenix S.A.U.
Osteoarthritis, Knee
Study of TG-C in Patients With Grade 3 Degenerative Joint Disease of the Knee
The purpose of this study is to see if we can safely regenerate cartilage without invasive surgery using a biologic product called TissueGene-C.
- Trial name
- NCT01221441
- Testing
- TissueGene-C, Normal Saline
- Where
- 5 sites in United States
- Volunteers
- 102 people
- Sponsor
- Kolon TissueGene, Inc.
Hepatocellular Carcinoma
to Evaluate the Efficacy and Safety of MG4101(Ex Vivo Expanded Allogeneic NK Cell)
To see the safety and efficacy of injecting MG4101 as a secondary treatment after curative liver resection on the patient with advanced HCC who has high risk of recurrence.
- Trial name
- MG4101 (NCT02008929)
- Testing
- MG4101
- Where
- South Korea
- Volunteers
- 5 people
- Sponsor
- Samsung Medical Center
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Diabetic Foot Ulcer (DFU), Venous Leg Ulcer (VLU)
Safety and Preliminary Efficacy of TrophiPatch, an Adipose-Derived Stromal Cell Patch for Chronic Leg Ulcers
This study aims to evaluate the safety and effectiveness of an experimental biological dressing called TrophiPatch, applied to adults with chronic leg ulcers of diabetic or vascular orign.
- Trial name
- RESCUE-PATCH (NCT07048054)
- Testing
- TrophiPatch: allogeneic adipose-derived stromal cell patch
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Nicolò Brembilla
Acute Myeloid Leukaemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
Safety and Efficacy of FT14 Conditioning for Allogeneic HSCT in Acute Myeloid Leukemia
This is a prospective, multicenter, phase II, open-label, non-randomized clinical trial designed to evaluate the safety and efficacy of the Fludarabine plus Treosulfan 14 g/m² (FT14) conditioning regimen for allogeneic stem cell…
- Trial name
- FT14 (NCT07232953)
- Testing
- Fludarabine + Treosulfan
- Where
- 13 sites in Italy
- Volunteers
- 82 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies
This is a phase I/II clinical trial to determine the maximum tolerated dose (MTD) of total marrow irradiation (TMI) followed by fludarabine in the context of a myeloablative conditioning regimen for allogeneic hematopoietic stem…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT05201183
- Testing
- Fludarabine + Total Marrow Irradiation
- Where
- United States
- Sponsor
- Naoyuki G. Saito, M.D., Ph.D.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.